Tag Archives: NICE guidance 2011

The Euro Heart Survey documented considerable variation in the management of patients with new-onset stable angina, due in part to uncertainties about the prognostic impact of both drug treatment and revascularisation. These uncertainties were inevitable given that much of the evidence used to guide management was incomplete and out of date. There have been further developments since the European Society of Cardiology guidelines on angina were published in 2006: these include better understanding of the efficacy and role of newer agents such as ivabradine and ranolazine, better understanding of secondary prevention measures, and refinements i

(more…)

The new guideline from the National Institute for Health and Clinical Excellence (NICE)1 covers adults who have been diagnosed with stable angina due to atherosclerotic disease, following on from clinical guideline 95,2 which advises on diagnosis of chest pain of recent onset. A key priority for implementation in the latest guidance is to ensure that people with stable angina receive balanced information and have the opportunity to discuss the benefits, limitations and risks of their treatment. Initial management of stable angina should be to offer optimal drug treatment, addressing both the angina itself and secondary prevention of cardiovas